Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
10/2006
10/11/2006EP1709020A2 Processes for preparing novel methylene blue derivative
10/11/2006CN1845909A Quinoxaline derivatives as neutrophil elastase inhibitors and their use
10/11/2006CN1279040C Tryasolyl tropane derivatives for therapy
10/11/2006CN1279023C Indole-3-sulphur derivatives
10/10/2006US7119086 Affinity and selectivity for arginine-vasopressin and/or ocytocin receptors; synthesis
10/10/2006CA2418778C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
10/10/2006CA2352554C Substituted benzimidazoles and their use as parp inhibitors
10/10/2006CA2350734C 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof
10/05/2006US20060223809 Thieno [2,3,-d]pyridazin-4(5H)-ones; modulation of autoimmune diseases with T-cell antiproliferatives; antiinflammatory; organ transplant rejection; AIDS; chronic obstructive pulmonary disease (COPD); asthma
10/04/2006EP1706393A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
10/04/2006EP1458376B1 Darifenacin for use in the treatment of urgency induced by overactive bladder
10/04/2006EP0956284B1 Process for selective derivatization of taxanes
10/03/2006US7115637 Inhibitors of p38
09/2006
09/28/2006US20060217413 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor
09/28/2006US20060217412 Imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
09/28/2006US20060217402 Biocidal compounds and their preparation
09/28/2006US20060217382 Imidazotriazine compounds
09/28/2006US20060217375 New compounds
09/27/2006EP1450792B1 Benzazole derivatives for the treatment of scleroderma
09/27/2006CN1839116A Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
09/27/2006CN1837205A Process for the preparation of pyrazolopyridine tartrates
09/27/2006CN1276921C Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics
09/26/2006US7112686 Precipitation from mother liquors by adding bases or acid addition salts to solution of citalopram
09/21/2006WO2005044794A3 Immunohistochemical methods
09/21/2006US20060211677 5-lipoxygenase activating protein inhibitors; antiatherosclerotic, antiasthmatic, antiallergic, antiinflammatory and cytoprotective agents
09/20/2006EP1702920A1 Pyrazole compounds useful as protein kinase inhibitors
09/20/2006EP1353916B1 Pyrazole compounds useful as protein kinase inhibitors
09/20/2006CN1835942A Mucin synthesis inhibitors
09/20/2006CN1275916C Novel intermediates useful for the preparation of antihistaminic piperidine derivatives
09/19/2006US7109339 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
09/14/2006WO2005019166A3 Method of targeting a therapeutic agent
09/14/2006US20060205931 Pharmaceutical compositions having appetite suppressant activity
09/14/2006US20060205802 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
09/14/2006US20060205783 inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis
09/14/2006US20060205696 [[2-(Amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
09/13/2006EP1699803A1 Novel compounds
09/13/2006EP1699779A1 1,2,3,4-tetrahydroisoquinoline derivatives, preparations thereof and uses thereof
09/13/2006CN1832943A Tetrahydropyran heterocyclic cyclopentyl heteroaryl modulators of chemokine receptor activity
09/13/2006CN1832925A New p2x7 receptor avtagonists and their use
09/13/2006CN1832741A Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
09/13/2006CN1830445A Tropane derivatives having therapy using, compounds and polymorph thereof
09/12/2006US7105562 2-methyl-6-[2-oxo-1,2-dihydro-indol-(3Z)-ylidene]1,4,5,6-tetrahydro-cyclopenta[b]pyrrole-3-carboxylic acid ethyl ester; disorders related to abnormal PK activity;
09/12/2006US7105537 For enhancing bone formation; for therapy of diseases or disorders associated with abnormal bone or mineral homeostasis
09/12/2006US7105530 Pyrimidineamines as angiogenesis modulators
09/07/2006US20060199821 Heterocyclic amides and sulfonamides
09/07/2006US20060199793 Sterol absorption inhibitor compounds
09/06/2006EP1698338A2 S-methyl-dihydro-ziprasidone for the treatment of schizophrenia
09/06/2006EP1697360A1 Novel crystalline forms of 2, 3 dimethyl-8- (2, 6-dimethylbenzylamino) -n-hydroxyethyl-imidazo 1, 2-a pyridine-6-carboxamide mesylate salt.
09/06/2006EP1696916A1 Use of metabotropic glutamate receptor 5 (mglur5) antagonists for the treatment of gastrointestinal disorders
09/06/2006CN1829711A Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
09/06/2006CN1829519A Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
09/06/2006CN1827108A Use of cytosine derivative for preparing drug for treating cancer
09/05/2006USRE39265 Heteroarylpiperidines, and their use as antipsychotics and analgetics
09/05/2006US7101877 Trans-[2-(4-Morpholinyl)-1-(2-Naphthenethoxy)]Cyclohexane Monohydrochloride; selectively inhibiting cardiac early repolarising currents and cardiac sodium currents
08/2006
08/31/2006WO2005077968A3 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
08/31/2006US20060194804 Hiv replication inhibiting pyrimidines and triazines
08/31/2006US20060194786 Process and intermediates for preparing benzazepines
08/30/2006CN1826343A Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
08/30/2006CN1826333A Diamine derivatives
08/30/2006CN1826131A Formation of novel erythropoietin conjugates using transglutaminase
08/30/2006CN1826121A Method for modulating calcium ion-release-activated calcium ion channels
08/30/2006CN1826120A Compounds for inflammation and immune-related uses
08/30/2006CN1826116A Piperidine derivatives as melanocortin-4 receptor agonists
08/30/2006CN1824656A Methods and compositions utilizing quinazolinones
08/30/2006CN1823749A Sertraline salts and sustained-release dosage forms of sertraline
08/30/2006CN1272319C Process for making amlodipine maleate
08/29/2006US7098337 Serotonin receptor agonists such as 6-chloro-4-methyl-1,2,3,4 -tetrahydro-2,4a,5-triaza-fluorene, used for prophylaxis of nervous system, cardiovascular, gastrointestinal, eating or sleep disorders, and as antidiabetic agents
08/29/2006US7098200 Analgesics
08/24/2006WO2005116002B1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
08/24/2006US20060189808 Heterocyclic inhibitors of MEK and methods of use thereof
08/24/2006US20060189668 Method of treating hyperproliferative disorders using heterocyclic inhibitors of MEK
08/24/2006US20060189649 Mitogen activated protein kinase inhibitors such as 6-(4-bromo-2-chlorophenylamino)-7-fluoro-3-methylbenzo[d]isoxazole-5-carboxylic acid (2-hydroxyethoxy)-amide, used in the treatment of hyperproliferative diseases, such as cancer and inflammation in mammals
08/24/2006US20060189632 MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine
08/24/2006US20060189615 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
08/24/2006US20060189600 Benodiazepine spirohydantoin cgrp receptor antagonists
08/23/2006EP1692153A2 Inhibition of syk kinase expression
08/23/2006EP1692102A2 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
08/23/2006EP1691837A2 Ip-10 antibodies and their uses
08/23/2006EP1278747B1 Pyrano, piperidino, and thiopyrano compounds and methods of use
08/23/2006CN1823040A Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
08/23/2006CN1821236A Therapeutic heterocyclic compounds
08/23/2006CN1821226A Antipicornaviral compounds, their preparation and use
08/22/2006US7094792 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
08/22/2006US7094764 Substituted benzimidazole-, Benztriazole-, and benzimidazolone-O-glucosides
08/17/2006US20060183896 Optically active quaternary ammonium salt, process for producing the same, and process for producing optically active alpha-amino acid derivative with the same
08/17/2006US20060183780 Lipoxygenase (e.g. 15-lipoxygenase) inhbitors; less toxic; longer acting; more potent; fewer side effects; easily absorbed; higher oral bioavailability and/or lower clearance; 4-Methyl-1-(pyridine-2-sulfonyl)pyrazole-3-carboxylic acid (2-chloro-4-fluorophenyl)amide
08/17/2006US20060183739 Carbonyl compounds
08/17/2006US20060179585 Sulfonamide derviatives of polycyclic dyes used for analytical applications
08/16/2006EP1690853A1 W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
08/16/2006EP1689736A2 Biocidal siloxane coating material containing n-halogenated amine and amide functional groups
08/16/2006EP1689406A2 Heterocyclic inhibitors of mek and methods of use thereof
08/16/2006EP1689389A2 Indole compounds
08/16/2006EP1689387A2 Bicyclic inhibitors of mek and methods of use thereof
08/16/2006EP1689233A2 Bicyclic inhibitors of mek and methods of use thereof
08/16/2006CN1817882A Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
08/16/2006CN1817872A Process for the preparation of substituted octanoyl amides
08/15/2006US7091364 Introducing in a reactor a5-amino-3-(carboxyalkyl)-4-cyano-2-thiophenecarboxylic acid, potassium carbonate and a quaternaryammonium salt as catalyst acetone solvent and methyl bromo acetate, heating and cooling
08/15/2006US7091197 Beta-lactamase inhibitor prodrug
08/10/2006US20060178370 Ketopiperazine derivatives as bradykinin antagonists
08/09/2006EP1688418A2 Chemokine receptor antagonists and methods of use thereof
1 ... 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 ... 105